SETBP1 and myelodysplastic syndrome: Although they found that MDS and CMML patients exhibiting SETBP1 mutations had significantly worse prognosis than their wild-type counterparts, there was—similar to Elliott et al.’s findings18—no significant effect of SETBP1 mutations on prognosis in CNL, though both these studies were limited by relatively small sample sizes136.